$54.83
+2.41 (+4.60%)
CRSP News3 articles
CRISPR Therapeutics Shares Slide 11.6% as Casgevy Faces Revenue Test
CRISPR Therapeutics shares fell 11.6% Friday as investors weigh Casgevy's market performance and upcoming governance decisions.
Intellia's CRISPR Therapy for HAE Nears FDA Filing After Late-Stage Success
Intellia Therapeutics (NTLA) announced its CRISPR therapy lonvo-z cut HAE attacks by 87% vs placebo in a Phase 3 trial, with 62% of patients attack-free. A rolling FDA submission has begun.
Intellia Shares Surge on Eve of Historic CRISPR Phase 3 Data Release
Intellia Therapeutics shares rallied 19.3% after hours Friday as investors await Phase 3 data from its HAELO trial of lonvoguran ziclumeran, an in vivo CRISPR gene-editing therapy for hereditary angioedema.